Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 5/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679250 | 0.92 | DHFR (0.36) | PHGDHSUV39H2CYP3A4LMNAHSD17B10 | |
| SCHEMBL7057399 | 0.91 | SUV39H2 (0.30) | SUV39H2 | |
| SCHEMBL6671882 | 0.91 | PHGDH (0.37) | PHGDHSUV39H2CYP3A4LMNAHSD17B10 | |
| SCHEMBL6673060 | 0.90 | PHGDH (0.36) | PHGDHSUV39H2MEN1KMT2A | |
| SCHEMBL6678191 | 0.90 | HTT (0.31) | — | |
| SCHEMBL6896764 | 0.89 | PHGDH (0.36) | PHGDHSUV39H2CYP3A4LMNAHSD17B10 | |
| SCHEMBL6674780 | 0.87 | PHGDH (0.36) | PHGDHCYP3A4LMNAHSD17B10MEN1 | |
| SCHEMBL6678058 | 0.85 | LMNA (0.34) | PHGDHLMNAHSD17B10MEN1KMT2A | |
| SCHEMBL6675481 | 0.84 | HTR7 (0.35) | LMNAPKMKMT2A | |
| SCHEMBL6678709 | 0.82 | DRD2 (0.35) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1424072-A1 | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-06-02 | — | — | EP | disclosed |
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | PHGDH 2923/4885SUV39H2 3367/4885CYP3A4 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.